Lithera is advancing LIPO-202 (Salmeterol Xinafoate for Injection), a novel, physician-administered injectable designed to produce localized non-ablative reduction of subcutaneous abdominal fat, currently in clinical development for central abdominal bulging in non-obese patients. The company is also developing LIPO-102 (Salmeterol Xinafoate and Fluticasone Propionate for Injection) for symptomatic exophthalmos associated with thyroid-related eye disease (Graves’ Orbitopathy). Lithera intends to use the latest funds for general corporate and working capital purposes, primarily to support clinical, regulatory, and manufacturing efforts to advance LIPO-202. The company is led by President and CEO George Mahaffey. Lithera was founded in 2007 and is based in San Diego, California. The recent financing activity reflects ongoing support from specialty life‑science investors for its clinical-stage programs.

Total raised

$8M

Funding rounds

1

Latest round

Series C

Latest activity

Feb 2014